WayPoint Biomedical Accepted as Full Member Into the HIRA Organization

HUNTINGTON BEACH, Calif., July 12  /PRNewswire-FirstCall/ -- WayPoint Biomedical Holdings, Inc. (Pink Sheets: WYPH) has been accepted as a full member into the Health Industry Representatives Association (HIRA).  The Health Industry Representatives Association focuses on promoting the manufacturers' rep function within the healthcare industry.  Its members are independent sales agencies located across the nation who offer manufacturers a professional, highly qualified sales force.  Additionally, allied members are manufacturers who support the continuing use of independent sales agencies to market their products.

HIRA has been in existence since 1980 and enjoys a well respected position in the Health Care Industry with Manufacturers, Distributors and Rep Groups across the USA.  HIRA also conducts focus groups, helps promote new member exposure and coordinates a national trade show each year to allow Manufacturers and Distributor/Rep groups to view new and exciting products and services.

Global Director of Sales & Marketing, Phill Richer, states, "WayPoint's acceptance by the HIRA organization will increase the exposure of the company to hundreds of new manufacturers and rep groups across the USA.  We plan to work very closely with the members and organization to promote and secure new sources of revenue for our Health Essist(TM) group of products and our Clinical Drugs of abuse tests."

  For more information on HIRA, please visit http://www.hira.org/ .

  About WayPoint Biomedical:


WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (Pink sheets: WYPH), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment.  The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition.  WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare.  The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science.  For more information on WayPoint Biomedical visit http://www.waypointbiomedical.com/ , http://www.drinkdetectiveusa.com/ .

Included in this release are certain "forward-looking' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance.  Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements.  In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political  conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Dennis Shepherd, 714-848-3200

E-mail:  

DATASOURCE: WayPoint Biomedical, Inc.



CONTACT:  Dennis Shepherd of WayPoint Biomedical, Inc., [phone],





Web site:  http://www.drinkdetectiveusa.com/ 

Web site:  http://www.hira.org/ 

Web site:  http://www.waypointbiomedical.com/ 

Copyright